| Literature DB >> 30596194 |
Olutosin A Awolude1, Sunday O Oyerinde2.
Abstract
BACKGROUND: Human Papillomavirus (HPV) infection persistence is the necessary but not sufficient cause of invasive cervical cancer (ICC). The effects of Human Immunodeficiency Virus (HIV) co-infection have been well documented. The purpose of this study was to describe our experience on the clinico-pathological characteristics of patients with cervical cancer and HIV status at a tertiary Hospital in Nigeria.Entities:
Keywords: Co-Infection; HIV; HPV; Invasive cervical cancer
Year: 2018 PMID: 30596194 PMCID: PMC6305076 DOI: 10.21010/ajid.v13i1.4
Source DB: PubMed Journal: Afr J Infect Dis ISSN: 2006-0165
Figure 1HIV Positivity Rate among the Patients
Sociodemographic Characteristics of Respondents
| Characteristics | Aggregate | Positive N=16 | Negative N=218 | Declined N=14 | |
|---|---|---|---|---|---|
| 55.4 [SD±10.2] | 44.6 [SD±11.7] | 56.2 [SD±9.8] | 54.6 [SD±8.6] | ||
| 21 [SD±10.2] | 18 [SD±4.4] | 22 [SD±3.4]. | 24.5 [SD±4.4] | ||
| 4 | 1 | 2 | |||
| Yes | 24 (9.7%) | 3 (18.8%) | 19 (8.7%) | 2 (14.3%) | |
| No | 224 (90.3%) | 13(81.3%) | 199(91.3%) | 12 (85.7%) | |
| Married | 181 (73.0%) | 12 (75.0%) | 156(71.6%) | 10(71.4%) | |
| Widowed | 62 (25.0%) | 3 (18.8%) | 57(26.1%) | 2(14.3%) | |
| Single | 5 (92.0%) | 1(6.2%) | 2(0.9%) | 2(14.3%) | |
| 0 1- | 4 (1.6%) | 1(6.3%) | 2(0.9%) | 1(7.1%) | |
| 4 | 56 (22.6%) | 11(68.8%) | 40(18.3%) | 5(3.6%) | |
| ≥5 | 188 (75.8%) | 4(25.0%) | 176(80.7%) | 8(5.7%) | |
| None | 91 (36.7%) | 5(31.3%) | 85939.0%) | 1(7.1%) | |
| Primary | 74 (29.8%) | 4(25.0%) | 68(31.2%) | 2(14.3%) | |
| Secondary | 51 (20.6%) | 5(25.0%) | 42(19.3%) | 4(28.6%) | |
| Tertiary | 32 (12.9%) | 2(6.3%) | 23(10.6%) | 7(50.0%) | |
Clinical Stages at Presentation
| Clinical Stages at Presentation | Total (N=248) | HIV Positive (n=16) | HIV Negative (n=218) | HIV Decline (n=14) | |
|---|---|---|---|---|---|
| 1b | 23(9.3%) | 0(0.0%) | 23(10.6%) | 0 | |
| 2b | 31(12.5%) | 3(18.8%) | 25(11.5%) | 3(21.4%) | |
| 3a | 88(35.5%) | 6(37.5%) | 76(34.9%) | 6(42.9%) | |
| 3b | 50(20.2%) | 4(25.0%) | 44(20.2%) | 2(14.3%) | |
| 4a | 5(2.0%) | 1(6.3%) | 3(1.4%) | 1(7.1%) | |
| 4b | 2(0.8%) | 1(6.3%) | 1(0.5%) | 0(0.0%) | |
Histological Types
| Histological Types | Total | HIV Status | ||
|---|---|---|---|---|
| N = 248 (%) | HIV positive N = 16 (%) | HIV negative N = 218 (%) | HIV Decline N = 13 | |
| Squamous cell carcinoma | 220 (88.7) | 12 (75.0) | 198 (90.8) | 10 (76.9) |
| Adenocarcinoma | 18 (7.3) | 3 (18.8) | 13 (6.0) | 2 (15.4) |
| Adenosquamous carcinoma | 6 (2.4) | 1(6.2) | 4(1.8) | 1(7.7) |
| Others | 4 (1.6) | 0 | 3 (1.4) | 1 (7.7) |
Others - Endometrial adenocarcinoma with cervix extension; small cell carcinoma (neuroendocrine